GT Biopharma Announces Issuance of Two New Patents Covering TriKE® Platform Technologies

BEVERLY HILLS, Calif.: BEVERLY HILLS, Calif., Sept. 9, 2021 /PRNewswire/ -- GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® protein biologic technology platform, today announced that the United States Patent...

Click to view original post